Xi'an International Medical Investment Future Growth

Future criteria checks 5/6

Xi'an International Medical Investment is forecast to grow earnings and revenue by 104.9% and 21.6% per annum respectively. EPS is expected to grow by 128.4% per annum. Return on equity is forecast to be 8.2% in 3 years.

Key information

104.9%

Earnings growth rate

128.4%

EPS growth rate

Healthcare earnings growth	22.8%
Revenue growth rate	21.6%
Future return on equity	8.2%
Analyst coverage	Low
Last updated	29 Oct 2024

Recent future growth updates

No updates

Recent updates

Xi'an International Medical Investment (SZSE:000516) Is Making Moderate Use Of Debt

Nov 21

After Leaping 27% Xi'an International Medical Investment Company Limited (SZSE:000516) Shares Are Not Flying Under The Radar

Oct 01

Xi'an International Medical Investment (SZSE:000516) Is Carrying A Fair Bit Of Debt

Jul 16

Investors Still Waiting For A Pull Back In Xi'an International Medical Investment Company Limited (SZSE:000516)

Jun 20

Does Xi'an International Medical Investment (SZSE:000516) Have A Healthy Balance Sheet?

Mar 25

Xi'an International Medical Investment Company Limited (SZSE:000516) Not Lagging Industry On Growth Or Pricing

Feb 28

Earnings and Revenue Growth Forecasts

SZSE:000516 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	7,761	381	N/A	1,206	1
12/31/2025	7,077	320	N/A	1,351	2
12/31/2024	5,478	100	N/A	652	1
9/30/2024	4,880	-358	419	1,022	N/A
6/30/2024	4,829	-320	504	1,203	N/A
3/31/2024	4,732	-399	510	1,084	N/A
12/31/2023	4,618	-368	325	1,087	N/A
9/30/2023	4,141	-572	116	1,153	N/A
6/30/2023	3,853	-803	59	1,074	N/A
3/31/2023	3,465	-823	-650	891	N/A
1/1/2023	2,711	-1,177	-727	461	N/A
9/30/2022	2,786	-1,064	-940	294	N/A
6/30/2022	2,683	-1,058	-1,269	176	N/A
3/31/2022	2,594	-1,068	-832	184	N/A
12/31/2021	2,921	-822	-1,203	456	N/A
9/30/2021	2,583	-41	-1,096	374	N/A
6/30/2021	2,273	30	-1,174	379	N/A
3/31/2021	1,964	52	-1,401	252	N/A
12/31/2020	1,607	45	-1,297	41	N/A
9/30/2020	1,391	-882	-2,168	-285	N/A
6/30/2020	1,188	-753	-2,627	-422	N/A
3/31/2020	1,046	-622	-3,378	-313	N/A
12/31/2019	991	-404	-3,647	-34	N/A
9/30/2019	896	-68	-3,460	128	N/A
6/30/2019	872	-19	-3,775	-554	N/A
3/31/2019	1,108	2,193	-3,010	-622	N/A
12/31/2018	2,039	2,184	-2,471	-772	N/A
9/30/2018	2,973	2,244	-1,607	-496	N/A
6/30/2018	3,617	2,280	N/A	203	N/A
3/31/2018	4,130	152	N/A	424	N/A
12/31/2017	4,060	195	N/A	384	N/A
9/30/2017	4,024	190	N/A	335	N/A
6/30/2017	3,984	191	N/A	395	N/A
3/31/2017	3,944	214	N/A	415	N/A
12/31/2016	3,931	202	N/A	439	N/A
9/30/2016	3,872	260	N/A	362	N/A
6/30/2016	3,866	217	N/A	350	N/A
3/31/2016	3,866	197	N/A	260	N/A
12/31/2015	3,900	241	N/A	274	N/A
9/30/2015	3,927	328	N/A	262	N/A
6/30/2015	3,960	369	N/A	292	N/A
3/31/2015	3,929	382	N/A	318	N/A
12/31/2014	3,883	350	N/A	306	N/A
9/30/2014	3,786	213	N/A	399	N/A
6/30/2014	3,645	168	N/A	337	N/A
3/31/2014	3,604	142	N/A	241	N/A
12/31/2013	3,566	122	N/A	328	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 000516 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).

Earnings vs Market: 000516 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 000516 is expected to become profitable in the next 3 years.

Revenue vs Market: 000516's revenue (21.6% per year) is forecast to grow faster than the CN market (13.7% per year).

High Growth Revenue: 000516's revenue (21.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 000516's Return on Equity is forecast to be low in 3 years time (8.2%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/30 04:48
End of Day Share Price	2024/12/30 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xi'an International Medical Investment Company Limited is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Min Qiu	China Merchants Securities Co. Ltd.
Zhu Chen	Citic Securities Co., Ltd.
Mujun Shen	Citic Securities Co., Ltd.

Xi'an International Medical Investment Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Recent updates

Xi'an International Medical Investment (SZSE:000516) Is Making Moderate Use Of Debt

Third quarter 2024 earnings released: CN¥0.018 loss per share (vs CN¥0 in 3Q 2023)

After Leaping 27% Xi'an International Medical Investment Company Limited (SZSE:000516) Shares Are Not Flying Under The Radar

Xi'an International Medical Investment Company Limited to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: CN¥0.03 loss per share (vs CN¥0.065 loss in 2Q 2023)

Xi'an International Medical Investment (SZSE:000516) Is Carrying A Fair Bit Of Debt

Xi'an International Medical Investment Company Limited to Report First Half, 2024 Results on Aug 28, 2024

Investors Still Waiting For A Pull Back In Xi'an International Medical Investment Company Limited (SZSE:000516)

Xi'an International Medical Investment Company Limited (SZSE:000516) commences an Equity Buyback Plan for CNY 150 million worth of its shares, under the authorization approved on May 20, 2024.

Xi'an International Medical Investment Company Limited, Annual General Meeting, May 20, 2024

First quarter 2024 earnings released: CN¥0.046 loss per share (vs CN¥0.033 loss in 1Q 2023)

Xi'an International Medical Investment Company Limited to Report Q1, 2024 Results on Apr 26, 2024

Does Xi'an International Medical Investment (SZSE:000516) Have A Healthy Balance Sheet?

Xi'an International Medical Investment Company Limited (SZSE:000516) Not Lagging Industry On Growth Or Pricing

Xi'an International Medical Investment Company Limited to Report Fiscal Year 2023 Results on Apr 26, 2024

Xi'an International Medical Investment Company Limited(SZSE:000516) dropped from Shenzhen Stock Exchange Component A Share Index

Third quarter 2023 earnings released: EPS: CN¥0 (vs CN¥0.10 loss in 3Q 2022)

Xi'an International Medical Investment Company Limited to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: CN¥0.065 loss per share (vs CN¥0.074 loss in 2Q 2022)

Now 21% undervalued after recent price drop

First quarter 2023 earnings released: CN¥0.033 loss per share (vs CN¥0.19 loss in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.10 loss per share (vs CN¥0.099 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.074 loss per share (vs CN¥0.072 loss in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Xi'an International Medical Investment Company Limited(SZSE:000516) dropped from Shenzhen Stock Exchange Component Index

Xi'an International Medical Investment Company Limited(XSEC:000516) dropped from FTSE All-World Index (USD)

Third quarter 2021 earnings released: CN¥0.099 loss per share (vs CN¥0.08 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.072 loss per share (vs CN¥0.079 loss in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.03 (vs CN¥0.21 loss in FY 2019)

New 90-day high: CN¥13.03

New 90-day high: CN¥9.25

New 90-day high: CN¥8.60

Third quarter earnings released

New 90-day high: CN¥7.87

New 90-day high: CN¥7.52

New 90-day high: CN¥7.04

First half earnings released

Xi'an International Medical Investment Company Limited to Report First Half, 2020 Results on Aug 28, 2020

Xi'an International Medical Investment Company Limited announced that it expects to receive CNY 1 billion in funding from Shaanxi Century Xinyuan Commercial Management Co., Ltd.